NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added
Policy / Regulatory

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added

The National Medical Products Administration (NMPA) has released the 110th batch of the Catalog of Reference Listed Drugs (RLD) for Chemical Generic Drugs, adding 28 new drug specifications and providing…

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma
CompanyDrug

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China
CompanyDrug

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

FDA Approves Priovant's LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication
CompanyDrug

FDA Approves Priovant’s LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication

Bio‑Thera's BAT2306 Becomes World's First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis
CompanyDrug

Bio‑Thera’s BAT2306 Becomes World’s First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer's Treatment Access
CompanyDrug

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer’s Treatment Access

ZEGFROVY (sunvozertinib) Officially Launches in the U.S. as Dizal and AstraZeneca Bring First Oral EGFR TKI Option to Pretreated Exon 20 Insertion NSCLC
CompanyDrug

ZEGFROVY (sunvozertinib) Officially Launches in the U.S. as Dizal and AstraZeneca Bring First Oral EGFR TKI Option to Pretreated Exon 20 Insertion NSCLC

Harbour BioMed's Batoclimab Wins NMPA Marketing Approval in China – First‑Class FcRn Antibody Now Indicated for AChR‑Positive Generalized Myasthenia Gravis
CompanyDrug

Harbour BioMed’s Batoclimab Wins NMPA Marketing Approval in China – First‑Class FcRn Antibody Now Indicated for AChR‑Positive Generalized Myasthenia Gravis

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

Johnson & Johnson (J&J) (NYSE: JNJ) announced that China's National Medical Products Administration (NMPA) has approved a new indication for Tecvayli (teclistamab injection) for adult patients with relapsed or refractory multiple myeloma (MM) who have received at least one prior…

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Ipsen Raises Full‑Year 2026 Guidance as 9M Sales Surge 23.0% to EUR 3.36 Billion – Rare Disease Doubles and Oncology Accelerates Ahead of Somatuline Generic Entry
Company

Ipsen Raises Full‑Year 2026 Guidance as 9M Sales Surge 23.0% to EUR 3.36 Billion – Rare Disease Doubles and Oncology Accelerates Ahead of Somatuline Generic Entry

Merck's Welireg (belzutifan) Wins NMPA Approval in China for Pheochromocytoma and Paraganglioma – Second Chinese Indication for the First‑in‑Class HIF‑2α Inhibitor
CompanyDrug

Merck’s Welireg (belzutifan) Wins NMPA Approval in China for Pheochromocytoma and Paraganglioma – Second Chinese Indication for the First‑in‑Class HIF‑2α Inhibitor

Novo Nordisk Secures NMPA Indication Update for Wegovy (semaglutide) in China – Expanded Label Now Covers Chinese BMI Criteria for Overweight and Obesity
CompanyDrug

Novo Nordisk Secures NMPA Indication Update for Wegovy (semaglutide) in China – Expanded Label Now Covers Chinese BMI Criteria for Overweight and Obesity

Sunshine Guojian Posts 24.77% Revenue Growth in First Three Quarters of 2026 as Anmuquitamab and Anfrequitamab Approvals Reshape Its Autoimmune Franchise
Company

Sunshine Guojian Posts 24.77% Revenue Growth in First Three Quarters of 2026 as Anmuquitamab and Anfrequitamab Approvals Reshape Its Autoimmune Franchise

Sichuan Biokin's Izalontamab Brengitecan (BL‑B01D1) Gains NMPA Acceptance for HR+/HER2‑ Breast Cancer NDA – Phase III PFS Win Drives Third Tumor‑Type Expansion Bid
CompanyDrug

Sichuan Biokin’s Izalontamab Brengitecan (BL‑B01D1) Gains NMPA Acceptance for HR+/HER2‑ Breast Cancer NDA – Phase III PFS Win Drives Third Tumor‑Type Expansion Bid

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide
CompanyDeals

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has entered into a definitive agreement with PepStar Therapeutics Limited to acquire its lead asset, HCXT‑2001, an investigational Phase I oral IL‑23…

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio
CompanyDeals

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline
CompanyDeals

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing
CompanyDeals

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing

Reju Therapeutics Completes Oversubscribed Series A Financing of Hundreds of Millions of RMB – China's First Senotherapeutics Biotech Backed by Top-Tier Investors
CompanyDeals

Reju Therapeutics Completes Oversubscribed Series A Financing of Hundreds of Millions of RMB – China’s First Senotherapeutics Biotech Backed by Top-Tier Investors

- Advertisement -
Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing
Policy / Regulatory

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Pilot Plan for Promoting the Research and Application of New Approach Methodologies (the "Pioneer Plan"),…

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
Policy / Regulatory

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition
Policy / Regulatory

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs
Policy / Regulatory

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs

More News

Sino Biopharm's CTTQ Wins China's First Generic Approval for TQC3403 Umeclidinium/Vilanterol Inhaler – Head‑to‑Head Phase III Equivalence Backs COPD Maintenance Launch
Others

Sino Biopharm’s CTTQ Wins China’s First Generic Approval for TQC3403 Umeclidinium/Vilanterol Inhaler – Head‑to‑Head Phase III Equivalence Backs COPD Maintenance Launch

Everest Medicines Secures TFDA Approval for Velsipity (etrasimod) in Ulcerative Colitis – Completion of All Authorized Territories Across Greater China and South Korea
CompanyDrug

Everest Medicines Secures TFDA Approval for Velsipity (etrasimod) in Ulcerative Colitis – Completion of All Authorized Territories Across Greater China and South Korea

Patronus Biotech Secures Ethics Approval to Launch Phase I Trials of Three Multi‑Stage U‑VLP Malaria Vaccine Candidates – First‑in‑Human Study of LYB014, LYB017 and LYB027 Set to Begin in Australia
CompanyDrug

Patronus Biotech Secures Ethics Approval to Launch Phase I Trials of Three Multi‑Stage U‑VLP Malaria Vaccine Candidates – First‑in‑Human Study of LYB014, LYB017 and LYB027 Set to Begin in Australia

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas
CompanyDrug

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

Enhertu Approved in China as First Tumor-Agnostic HER2-Targeted Therapy – Daiichi Sankyo's ADC Wins Conditional Approval for HER2-Expressing Solid Tumors
CompanyDrug

Enhertu Approved in China as First Tumor-Agnostic HER2-Targeted Therapy – Daiichi Sankyo’s ADC Wins Conditional Approval for HER2-Expressing Solid Tumors

Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed
Company

Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed

European Commission Approves Novartis' Cosentyx for Polymyalgia Rheumatica – First and Only IL-17A Inhibitor for Adult PMR in Europe
CompanyDrug

European Commission Approves Novartis’ Cosentyx for Polymyalgia Rheumatica – First and Only IL-17A Inhibitor for Adult PMR in Europe

LongBio Pharma Reports Positive Top-Line Phase II Data for LP-005 – Bifunctional C5/C3b Antibody Achieves 100% Hemolysis Control in PNH
CompanyDrug

LongBio Pharma Reports Positive Top-Line Phase II Data for LP-005 – Bifunctional C5/C3b Antibody Achieves 100% Hemolysis Control in PNH

Show More